Here is what I have from late June, 2014 (there seems to be 8 new/open positions since June 30th listed):
Program (Project) Manager - Technical Operations Finance Monmouth Junction, NJ (still open)
Associate Director, Quality Assurance - GCP Quality Assurance Monmouth Junction, NJ (still open)
Director, Clinical Development Clinical Bridgewater, NJ (filled or deleted)
Receptionist Bridgewater, NJ (filled etc.)
Commercial Compliance Counsel Legal Bridgewater, NJ (still open)
Senior Quality Assurance Specialist/Manager - GCP Quality Assurance Monmouth Junction, NJ (filled etc)
Regulatory Associate Regulatory Affairs Monmouth Junction, NJ (still open)
Program Manager - Commercial Finance Monmouth Junction, NJ (looks to be still open)
Senior Clinical Research Scientist Clinical Monmouth Junction, NJ (filled etc.)
Marketing Director, Digital Commercialization Bridgewater, NJ (filled or deleted)
Biostatistician Medical Affairs Monmouth Junction, NJ (filled or deleted)
According to the Insmed website, she is still with thy company (as special advisor).
Also, they have 13 open positions, of which many look to be over 5 months old. So, why have they
not been filled?
from NASDAQ (up almost 1.5%). Insmed is still below my $14 target (LOL) at least for today. Many of my BIOs are floundering even NVAX (ECYT sucks (sorry)).
Russell 2000 is down significantly this year. BIOs have been mostly "crushed" since end of March. but, having said that, and seeing the NASDAQ pre-market is getting bludgeoned again, you may be timely after all. So what is your target? $11 or ??
Franklin added 5000 shares, Creative Planning sold (wait for it) 1 share!! LOL
jd - we may see a move over $14 today IF the premarket's current green status holds. Insmed held its own during this horrific sell off across BIO land.
Jad, aren't most of the Russell 2000 Bios down today (again)? I think Russell is down almost 10% this year.
Thx Historian, I believe it is the top 4 in this list:
Director, Health Economics and Outcomes Research - Global Medical Affairs Bridgewater, NJ
Associate Director, Medical Communications Medical Affairs Bridgewater, NJ
Facilities Manager Human Resources Bridgewater, NJ
Clinical Trial Project Manager Clinical Bridgewater, NJ
Manager, Employee Communications (Contract) Human Resources Bridgewater, NJ
Help Desk Associate (Part/Time) Information Technology Bridgewater, NJ
Associate Scientist - Analytical / Inhalation Research Bridgewater, NJ
Associate Director, Quality Assurance - GCP Quality Assurance Bridgewater, NJ
Program (Project) Manager - Technical Operations Finance Bridgewater, NJ
Regulatory Associate Regulatory Affairs Bridgewater, NJ
Director, Clinical Development Clinical Bridgewater, NJ
Commercial Compliance Counsel Legal Bridgewater, NJ
The Insmed of old is coming to life (back over $13 after touching $12.17). I was going to but some shares under $12.25 and I blinked.....LOL (I have quite enough already)
Endocyte just filed (lots of speculation) rumor (just a rumor) stated they met with Roche this past weekend but who knows- the death of me the last 5 months! thx
Confidential Treatment Order? I know it is sometimes used when the SEC does its occasional review so is that all it would be for? Jad, you forget my fake ID he used once - not sure what it was though..LOL
To further clarify, the SEC periodically (once every 3 years or so )will review a company's "books" and that company MAY file a CTO.
So, it could be a normal "audit" request by the SEC OR it could be a request from a "partner" (who knows?):
The CTO is is the technical document used to brief a potential partner/suitor. The same CTO,
could probably be used for multiple presentations to all interested parties (including the SEC).
maybe is helps but the timing makes sense (no matter what the market has done):
"Companies would typically seek a CTO in order to keep information that would otherwise put it at a disadvantage, a secret. For example, a company may apply for such an order to keep information regarding a pricing arrangement made with a partner, secret, since competitors finding out this information may go after the partner with a more competitive price."
Agree and that would only be $8/shr. We have 238M shares outstanding so IF a real offer comes along I would hope for double that ($3.5B). For now, let's get back to $5/shr please LOL
What makes this move suspect is Brean just re-initiated coverage as a "buy" with a PT of $22 July 10th (or thereabouts):
"Stock analysts at Brean Capital initiated coverage on shares of Endocyte (NASDAQ:ECYT) in a report issued on Tuesday. The firm set a “buy” rating and a $22.00 price target on the stock. Brean Capital’s price objective suggests a potential upside of 247.00% from the company’s current price ($6.34)"
Brean now lowers the "coverage" to hold and removed the PT altogether. Wedbush, Cantor, Cowen and Chardan see it differently but their coverage received no "airplay". Something nefarious going on behind the curtain?